BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 10980853)

  • 1. Is primary antiarrhythmic drug therapy for ventricular arrhythmias obsolete?
    Cooley R; Akhtar M; Sra J
    Curr Cardiol Rep; 1999 Nov; 1(4):268-73. PubMed ID: 10980853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Secondary prevention of sudden death: the Dutch Study, the Antiarrhythmics Versus Implantable Defibrillator Trial, the Cardiac Arrest Study Hamburg, and the Canadian Implantable Defibrillator Study.
    Cappato R
    Am J Cardiol; 1999 Mar; 83(5B):68D-73D. PubMed ID: 10089843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drugs versus devices in controlling ventricular tachycardia, ventricular fibrillation, and recurrent cardiac arrest.
    Haverkamp W; Eckardt L; Borggrefe M; Breithardt G
    Am J Cardiol; 1997 Oct; 80(8A):67G-73G. PubMed ID: 9354413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias.
    Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators
    N Engl J Med; 1997 Nov; 337(22):1576-83. PubMed ID: 9411221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic decision tree for patients with sustained ventricular tachyarrhythmias or aborted cardiac arrest: a critical review of the Antiarrhythmics Versus Implantable Defibrillator trial and the Canadian Implantable Defibrillator Study.
    Farré J; Cabrera JA; Romero J; Rubio JM
    Am J Cardiol; 2000 Nov; 86(9A):44K-51K. PubMed ID: 11084100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacologic therapy of ventricular tachyarrhythmias: value of class III anti-arrhythmia drugs].
    Haverkamp W; Borggrefe M; Block M; Böcker D; Breithardt G
    Z Kardiol; 1996; 85 Suppl 6():97-106. PubMed ID: 9064989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New primary prevention trials of sudden cardiac death in patients with left ventricular dysfunction: SCD-HEFT and MADIT-II.
    Klein H; Auricchio A; Reek S; Geller C
    Am J Cardiol; 1999 Mar; 83(5B):91D-97D. PubMed ID: 10089848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg . Canadian Implantable Defibrillator Study.
    Connolly SJ; Hallstrom AP; Cappato R; Schron EB; Kuck KH; Zipes DP; Greene HL; Boczor S; Domanski M; Follmann D; Gent M; Roberts RS
    Eur Heart J; 2000 Dec; 21(24):2071-8. PubMed ID: 11102258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Why the antiarrhythmics versus implantable defibrillator (AVID) trial sets the wrong precedent.
    Fogoros RN
    Am J Cardiol; 1997 Sep; 80(6):762-5. PubMed ID: 9315584
    [No Abstract]   [Full Text] [Related]  

  • 10. Sudden cardiac death: who needs an implantable cardioverter-defibrillator and who needs antiarrhythmic drugs?
    Ferrari R; Cinca J; Marber M
    Eur Heart J; 1999 Mar; 20(6):397-8. PubMed ID: 10213339
    [No Abstract]   [Full Text] [Related]  

  • 11. Antiarrhythmic drugs versus implantable defibrillators: the need for a randomized controlled study.
    Greene HL
    Am Heart J; 1994 Apr; 127(4 Pt 2):1171-8. PubMed ID: 8160597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ventricular Tachycardia with ICD Shocks: When to Medicate and When to Ablate.
    AbdelWahab A; Sapp J
    Curr Cardiol Rep; 2017 Sep; 19(11):105. PubMed ID: 28900864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiarrhythmic drugs or implantable cardioverter defibrillators in heart failure: the "poor heart".
    Böcker D; Breithardt G
    Am J Cardiol; 1999 Mar; 83(5B):83D-87D. PubMed ID: 10089846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amiodarone: clinical trials.
    Naccarelli GV; Wolbrette DL; Patel HM; Luck JC
    Curr Opin Cardiol; 2000 Jan; 15(1):64-72. PubMed ID: 10666663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dofetilide reduces the frequency of ventricular arrhythmias and implantable cardioverter defibrillator therapies.
    Baquero GA; Banchs JE; Depalma S; Young SK; Penny-Peterson ED; Samii SM; Wolbrette DL; Naccarelli GV; Gonzalez MD
    J Cardiovasc Electrophysiol; 2012 Mar; 23(3):296-301. PubMed ID: 21955243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implantable defibrillators and antiarrhythmic drugs in patients at risk for lethal arrhythmias.
    Zivin A; Bardy GH
    Am J Cardiol; 1999 Nov; 84(9A):63R-68R. PubMed ID: 10568662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antiarrhythmic therapy in patients with heart failure].
    Faber TS; Zehender M
    Ther Umsch; 2000 May; 57(5):324-32. PubMed ID: 10859993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term comparison of the implantable cardioverter defibrillator versus amiodarone: eleven-year follow-up of a subset of patients in the Canadian Implantable Defibrillator Study (CIDS).
    Bokhari F; Newman D; Greene M; Korley V; Mangat I; Dorian P
    Circulation; 2004 Jul; 110(2):112-6. PubMed ID: 15238454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Canadian implantable defibrillator study (CIDS) : a randomized trial of the implantable cardioverter defibrillator against amiodarone.
    Connolly SJ; Gent M; Roberts RS; Dorian P; Roy D; Sheldon RS; Mitchell LB; Green MS; Klein GJ; O'Brien B
    Circulation; 2000 Mar; 101(11):1297-302. PubMed ID: 10725290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary and secondary prevention of sudden cardiac death: the role of the implantable cardioverter defibrillator.
    Prystowsky EN
    Rev Cardiovasc Med; 2001; 2(4):197-205. PubMed ID: 12439369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.